Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Extended Data Table 1 Overview of pertinent patient characteristics, as well as BRAF status and total cycles of IT nivolumab received by dose level, patient accession number and outcome of patients
